Incremental value of magnetic resonance imaging for clinically high risk prostate cancer in 922 radical prostatectomies

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2054-2060

  Jeong, In Gab ^a   Lim, Ju Hyun ^a   You, Dalsan ^a   Kim, Mi Hyun ^a   Choi, Hyuk Jae ^a   Kim, Jeong Kon ^a   Cho, Kyoung Sik ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan   (South Korea)

Author keywords

Magnetic resonance imaging; Prognosis; Prostate; Prostatectomy; Prostatic neoplasms

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; SEMINAL VESICLE DISEASE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR INVASION;

EID: 84888641396     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.035     Document Type: Article

References (26)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10.
2. Thompson IM: Defining high risk prostate cancerdwhere do we set the bar? A translational science approach to risk stratification. J Urol 2006;176:S21.
3. Cooperberg MR, Cowan J, Broering JM et al: High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008;26:211.
4. D'Amico AV, Whittington R, Malkowicz SB et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969.
5. Yossepowitch O, Eggener SE, Serio AM et al: Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008;53:950.
6. Greene KL, Albertsen PC, Babaian RJ et al: Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232.
7. Wang L, Mullerad M, Chen HN et al: Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 2004;232:133.
8. Wang L, Hricak H, Kattan MW et al: Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006;186:743.
9. Wang L, Hricak H, Kattan MW et al: Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007;242:182.
10. Hoeks CM, Barentsz JO, Hambrock T et al: Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261:46.
11. Fuchsjager MH, Shukla-Dave A, Hricak H et al: Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int 2009;104:315.
12. D'Amico AV, Whittington R, Malkowicz B et al: Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000;164:759.
13. Poulakis V, Witzsch U, de Vries R et al: Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy. Eur Urol 2004;46:571.
14. Lim HK, Kim JK, Kim KA et al: Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detectionda multireader study. Radiology 2009;250:145.
15. Sala E, Akin O, Moskowitz CS et al: Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006;238:929.
16. Yu KK, Scheidler J, Hricak H et al: Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481.
17. Cookson MS, Aus G, Burnett AL et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540.
18. Yossepowitch O, Eggener SE, Bianco FJ Jr et al: Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178:493.
19. Loeb S, Schaeffer EM, Trock BJ et al: What are the outcomes of radical prostatectomy for highrisk prostate cancer? Urology 2010;76:710.
20. Sciarra A, Barentsz J, Bjartell A et al: Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59:962.
21. Joseph T, McKenna DA, Westphalen AC et al: Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009;73:665.
22. Park SY, Kim CK, Park BK et al: Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results. Eur Radiol 2011;21:1111.
23. Nishida K, Yuen S, Kamoi K et al: Incremental value of T2-weighted and diffusion-weighted MRI for prediction of biochemical recurrence after radical prostatectomy in clinically localized prostate cancer. Acta Radiol 2011;52:120.
24. Nepple KG, Rosevear HM, Stolpen AH et al: Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients. Urol Oncol 2013;31:601.
25. Brajtbord JS, Lavery HJ, Nabizada-Pace F et al: Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. BJU Int 2011;107:1419.
26. Barentsz JO, Richenberg J, Clements R et al: ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746.